AxoGen, Inc.

187 articles with AxoGen, Inc.

• Axogen RECON(SM) Clinical Study Completes Subject Follow-upRECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft

  9/1/2021

  Axogen, Inc. today announced that the RECON Clinical Study supporting its Biologics License Application (BLA) for Avance Nerve Graft has completed follow-up of study subjects.

• Axogen, Inc. Reports 2021 Second Quarter Financial Results

  8/4/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2021.

• Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

  7/22/2021

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that Karen Zaderej, chairman, CEO, and president will present at the Canaccord Genuity 41st Annual Growth Conference.

• Axogen, Inc. Appoints John H. Johnson to Board of DirectorsGlobal leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

  7/19/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of Directors, effective July 19, 2021.

• Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021

  7/14/2021

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.

• 

  Biopharma Execs Address the Challenges of a Post-Pandemic Workplace

  5/18/2021

  If these companies are any indication, it appears that the biopharma industry will be a hybrid of virtual and physical workforces, and with this comes a whole new set of risks.

• Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

  5/18/2021

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mariani, executive vice president and CFO will present at two upcoming investor conferences.

• Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference

  5/6/2021

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that Peter J. Mariani, executive vice president and chief financial officer will present at the Canaccord Genuity Musculoskeletal Conference.

• Axogen, Inc. Reports 2021 First Quarter Financial Results

  5/5/2021

  Axogen, Inc.Axogen, Inc.Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2021.

• Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021

  4/14/2021

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021 after the market closes.

• Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer

  3/1/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer.

• Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results

  2/22/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020.

• Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis

  2/18/2021

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced completion of pilot phase analysis for its REPOSE clinical study.

• Axogen, Inc. to Participate at Upcoming February Investor Conferences

  2/4/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February. Karen Zaderej, chairman, CEO, and president, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021 at 9:00 a.m

• Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021

  2/1/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report fourth quarter and full-year 2020 financial results on Monday, February 22, 2021

• Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020

  1/11/2021

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2020 revenue.

• Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings

  1/5/2021

  Clinical evidence supporting the company’s platform for nerve repair will be featured in several presentations during the scientific sessions

• Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration

  12/23/2020

  Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced their sponsorship of Donate Life at the annual Tournament of Roses® celebration.

• Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum

  11/4/2020

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming investor events – the Jefferies Virtual London Healthcare Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum.

• Axogen, Inc. Reports Third Quarter 2020 Financial Results

  10/29/2020

  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020